|
|
Cardiovascular Disease in Patients with Rheumatoid Arthritis: Results from the QUEST-RA Study
Theodore Pincus, MD
New York University Hospital for Joint Diseases
|
Treatment of Rheumatoid Arthritis With a Syk Kinase Inhibitor:
A Twelve-Week, Randomized, Placebo-Controlled Trial
Michael C. Weinblatt, MD
Brigham and Women's Hospital
|
Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis: Findings of a Fifty-Two–Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Edward Keystone, MD, FRCP(C)
University of Toronto
|
Efficacy and Safety of Abatacept or Infliximab vs. Placebo in ATTEST: A Phase III, Multi-centre, Randomised, Double-blind, Placebo-controlled Study in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Michael H. Schiff, MD
University of Colorado School of Medicine
|
IL-6 Receptor Inhibition with Tocilizumab Improves Treatment Outcomes in Patients with Rheumatoid Arthritis Refractory to Anti-TNF Biologics: Results from a 24-week Multicentre Randomised Placebo Controlled Trial
Paul Emery, MA, MD, FRCP
Leeds Teaching Hospital
|
American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Kenneth Saag, MD, MSc
University of Alabama
|
|
